Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NICE issues rituximab guidance

The Appraisals Committee of the U.K.'s National Institute for Clinical Excellence released a preliminary appraisal document recommending use of Idec's rituximab

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE